Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Immunogenicity Study of the Antibody Persistence and Booster Effect of PENTAXIM™ at 18 Months of Age Following a Primary Series of DTaP-IPV-HB-PRP~T Combined Vaccine or of PENTAXIM™ and ENGERIX B® PEDIATRICO at 2, 4, and 6 Months of Age in Healthy Argentinean Infants

NCT00303316 is registered in ClinicalTrials.gov with Sanofi as lead sponsor.

NCT NCT00303316
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00303316 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Immunogenicity Study of the Antibody Persistence and Booster Effect of PENTAXIM™ at 18 Months of Age Following a Primary Series of DTaP-IPV-HB-PRP~T Combined Vaccine or of PENTAXIM™ and ENGERIX B® PEDIATRICO at 2, 4, and 6 Months of Age in Healthy Argentinean Infants
Lead sponsor
Sanofi
Phase
Phase 3
Overall status
Completed
Start date
February 28, 2006
Completion date
September 30, 2007
Enrollment
458 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

diphtheria, hepatitis b, pertussis, poliomyelitis, tetanus